TIGERMED (03347.HK): Frontage Privatisation, Spin-Off Update
NewTimeSpace News: On 17 November 2026, Hangzhou Tigermed Consulting Co., Ltd. (stock code: 3347) issued a progress announcement on the privatisation and separation transaction of its subsidiary Frontage Holdings Corporation, disclosing the key audited financial data of Frontage for the year ended 31 December 2025 and the six months ended 30 June 2026.
According to the announcement, in US$'000, Frontage's total assets stood at 541,024, total liabilities at 192,978 and net assets at 348,046 for 2025, with operating revenue of 256,691 and net profit of 6,762; for the first half of 2026, total assets were 580,474, total liabilities 224,248 and net assets 356,226, with operating revenue of 148,190 and net profit of 6,788.
The Company cautioned that the transaction is subject to the fulfilment of pre-conditions and conditions and may or may not proceed, and advised shareholders and potential investors of the Company, the offeror or the offeree to exercise caution when dealing in the relevant securities.
- TIGERMED (03347.HK): buyback reaches 20.96m shares, RMB 824m
- TIGERMED (03347.HK): Controlling Shareholders Ye Xiaoping and Cao Xiaochun Receive Warning Letter and Administrative Penalty Pre-notice Over Shareholding-change Disclosure Violations; RMB 1 Million Fine Proposed
- Tigermed (03347.HK): Has repurchased A-shares with a total consideration of approximately RMB 824 million
- TIGERMED(03347.HK) will spend CNY 175.37 million to repurchase 4.44 million shares on Jun 12, 2026
- TIGERMED (03347.HK): Directors and Controlling Shareholders Ye Xiaoping and Cao Xiaochuan Placed Under CSRC Investigation